A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of Two Dose Regimens (60 mg/kg and 120 mg/kg) of Weekly Intravenous Alpha1 Proteinase Inhibitor (Human) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency
Phase of Trial: Phase III
Latest Information Update: 23 Oct 2019
Price : $35 *
At a glance
- Drugs Alpha 1-antitrypsin (Primary)
- Indications Emphysema
- Focus Registrational; Therapeutic Use
- Acronyms SPARTA
- Sponsors Grifols
- 14 Jul 2019 This trial has been completed in Spain.
- 29 Sep 2018 Planned End Date changed from 1 Aug 2021 to 1 Nov 2023.
- 29 Sep 2018 Planned primary completion date changed from 1 Aug 2021 to 1 Nov 2023.